|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C9orf16 |
Gene summary for C9ORF16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C9orf16 | Gene ID | 79095 |
| Gene name | bublin coiled coil protein | |
| Gene Alias | C9orf16 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9BUW7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79095 | C9orf16 | Dong_P3 | Human | Prostate | Tumor | 5.57e-19 | 4.30e-01 | 0.0278 |
| 79095 | C9orf16 | Dong_P4 | Human | Prostate | Tumor | 4.43e-05 | 1.57e-01 | 0.0292 |
| 79095 | C9orf16 | Dong_P5 | Human | Prostate | Tumor | 3.37e-18 | 2.51e-01 | 0.053 |
| 79095 | C9orf16 | P7 | Human | Prostate | Tumor | 1.60e-03 | 5.79e-01 | -0.1025 |
| 79095 | C9orf16 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.56e-03 | -7.54e-01 | 0.1557 |
| 79095 | C9orf16 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 7.71e-03 | -7.54e-01 | 0.1531 |
| 79095 | C9orf16 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 6.79e-10 | -7.09e-01 | 0.1633 |
| 79095 | C9orf16 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.19e-12 | -6.81e-01 | 0.1608 |
| 79095 | C9orf16 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 4.58e-06 | -6.68e-01 | 0.1604 |
| 79095 | C9orf16 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.27e-06 | -6.54e-01 | 0.1621 |
| 79095 | C9orf16 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 9.65e-04 | -7.12e-01 | 0.1619 |
| 79095 | C9orf16 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.56e-03 | -7.54e-01 | 0.159 |
| 79095 | C9orf16 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 3.18e-07 | -6.30e-01 | 0.1602 |
| 79095 | C9orf16 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 2.49e-03 | -6.39e-01 | 0.1608 |
| 79095 | C9orf16 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.52e-04 | -3.53e-01 | 0.1575 |
| 79095 | C9orf16 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 6.72e-23 | -7.34e-01 | 0.1545 |
| 79095 | C9orf16 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 3.69e-15 | -7.18e-01 | 0.1569 |
| 79095 | C9orf16 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 2.27e-02 | -7.54e-01 | 0.1541 |
| 79095 | C9orf16 | P4_S8_cSCC | Human | Skin | cSCC | 4.19e-07 | -4.08e-02 | -0.3095 |
| 79095 | C9orf16 | P5_S10_cSCC | Human | Skin | cSCC | 1.80e-07 | -6.70e-03 | -0.299 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C9orf16 | SNV | Missense_Mutation | c.210N>A | p.Phe70Leu | p.F70L | Q9BUW7 | protein_coding | tolerated(0.15) | possibly_damaging(0.77) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| C9orf16 | SNV | Missense_Mutation | novel | c.163C>A | p.Arg55Ser | p.R55S | Q9BUW7 | protein_coding | tolerated(0.07) | benign(0.297) | TCGA-55-6972-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |